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An outbreak of unexplained illness among heroin userswas reported in May 2000 in Dublin.1 Between 29 Apriland 26 June 2000, 22 cases were identified, with eight
deaths. This occurred in association with similar outbreaks in
the UK, particularly Glasgow. Illness was characterised by soft
tissue inflammation at the injection site, followed by hypoten-
sion and circulatory collapse. Laboratory results indicated that
clostridium species were associated with the outbreaks.2
Analysis of cases in the UK indicate increased risk for
female injectors and longer term users.3 However, data on
injecting practice were unavailable. Injecting intramuscularly
has been associated with outbreaks of wound botulism and
tetanus.4 5 A prospective case-control study was initiated to
identify risk factors associated with this outbreak.
PARTICIPANTS, METHODS, AND RESULTS
Interviews were conducted with case patients who met the
international case definition.1 Surrogates were used for
deceased cases and were defined as people who acknowledged
routinely injecting drugs in the company of, having a sexual
relationship with, or being a close partner or family member of
the case patient. Three surrogates were sought for each case
patient. A composite surrogate interview, extracted from the
interviews obtained for each case, was used in the final analy-
sis. Interviews with cases or surrogates were obtained from 19
of 22 cases. Two cases were untraceable and in one case all
surrogates refused.
At the time of the outbreak, after much publicity, injecting
drug users not in treatment came forward for emergency
assessment, and 100 were immediately given treatment. Sixty
five controls were chosen from this group. Controls were
therefore injecting drug users from the Dublin area who had
injected since 1 April 2000, and who had presented for emer-
gency treatment after publicity about the outbreak. Exclusion
criteria included hospitalisation for an abscess or a new local
inflammation during the previous two months. Written
consent was obtained for participation in the study, and
participants were paid £Ir10.
A questionnaire, developed in Glasgow andmodified for use
in Dublin,was administered by an interviewer.Questions were
asked about; demographics, drug use, routes of injection,
preparation of drugs to inject, sharing practices, sources of
heroin and cocaine, illness, and blood borne virus status. Data
were analysed using EpiInfo 6 and Jump In.
On univariate analysis, age group over 30 years, injecting for
more than five years, injecting four or more times per day,
injecting heroin of a lighter colour, injecting more than 1.0 g
per hit, and injecting into muscle were associated with illness
(OR>2). On multivariate analysis, only injecting heroin into
muscle remained as being independently associated with
illness (table 1).
COMMENT
Injecting into muscle is usually done when venous access is
difficult because of scarring of veins from repeated use. This is
consistent with our finding that cases were older and had been
injecting for longer lengths of time than controls.
Recommendations are difficult to make as injecting drug
use exposes the drug user to many perils. The injecting of
heroin or other drugs into muscle may expose users, particu-
larly older and longer term users, to dangers from infections
that thrive in an anaerobic environment. Needle exchange
programmes to prevent transmission of blood borne virus
among injectors may limit infection from shared use of inject-
ing equipment, but these measures may not be effective
against spores contained in the drug.
This outbreak brought many drug users forward for
treatment. The awareness among drug users of the need to








odds ratio 95% CI
Female sex 6/19 (32) 17/65 (26) 1.30 0.37 to 4.54
Age group 30+ 9/19 (47) 16/65 (25) 2.76 0.94 to 8.08 1.39 0.36 to 5.26
Length of time injecting >5 yrs 16/19 (84) 43/65 (66) 2.72 0.80 to 12.62 2.69 0.60 to 14.95
Blood borne viral status† (HIV/HBV/HCV) 11/19 (58) 26/65 (40) 1.26 0.44 to 3.56
Injecting heroin into vein 12/19 (63) 62/65 (95) 0.08 0.02 to 0.34*
Injecting heroin into muscle 17/19 (89) 15/65 (23) 28.33 7.09 to 192.2* 27.04 6.53 to 187.93
Injecting >4 times/day 10/17 (59) 20/61 (33) 2.93 0.98 to 9.18
Injecting cocaine 5/19 (26) 19/65 (29) 0.86 0.25 to 2.62
Polydrug use (heroin +) 6/19 (32) 24/47 (51) 0.44 0.14 to 1.32
Needle sharing 7/17 (41) 26/64 (41) 1.02 0.33 to 3.01
Sharing paraphernalia 16/18 (89) 59/65 (91) 0.81 0.17 to 5.91
Injecting heroin of lighter colour 15/16 (94) 49/64 (77) 4.59 0.82 to 86.4
Injecting heroin of darker colour 14/18 (78) 45/64 (70) 1.47 0.46 to 5.73
Injecting <0.5 g 2/13 (15) 23/60 (38) 0.29 0.04 to 1.22
Injecting 0.5–1.0 g 9/13 (69) 37/60 (62) 1.40 0.40 to 5.64
Injecting >1.0 g 3/13 (23) 5/60 (8) 3.30 0.60 to 15.81
*p Value <0.05; †reported positive status for one or more.
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treat abscesses and severe tissue inflammation was raised.
The critical factor in relation to the response to this outbreak
was the multiagency working as demonstrated by regular
meeting between the disciplines involved. Thus the accident
and emergency services, the Infectious Disease Services, the
Drugs Services, and the Public Health Service met on a
weekly basis to respond to the crisis. Expanded availability of
local treatment services and the quick response of both acci-
dent and emergency and drug treatment services to any
additional outbreaks will minimise death and illness in this
population.
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